The EndPandemic National Data Consortium has announced that it has received commitments from six life sciences and information technology companies to join the Consortium, the formation of which was announced on March 30, 2020. The companies will work together to achieve the singular goal of integrating data from all ongoing and future clinical studies to accelerate analysis on COVID-19 and SARS-CoV-2 research in order to reduce the time to find a cure by up to 50%.
“The new EndPandemic National Data Consortium partners are to be applauded for the speed with which they answered the call to protect and ensure public health,” said Kenneth Massey, PharmD, Chief Life Sciences Officer of Saama Technologies."The integrated database developed by the Consortium will be a comprehensive, collective platform that will inform and accelerate medical experts’ abilities to arrive at actionable decisions in relation to COVID-19 clinical research.”
The EndPandemic National Data Consortium’s value proposition, strategic direction, charter and business plan are being developed by Zaylan Associates and its partner Chrysalis Biomedical Advisors. The following organizations have pledged to bring their unique capabilities and global expertise to the EndPandemic National Data Consortium to facilitate clinical trial data sharing among and across biopharmaceutical, research, healthcare, and government sectors, and create a continuously-updated data repository that will generate insights for researchers worldwide:
The EndPandemic National Data Consortium welcomes other biopharmaceutical companies, clinical research organizations, data analytics leaders, and government agencies to join. Interested organizations can contact info@endpandemic.org or call 888.970.3550.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.